Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 6/20 | 0.44 |
| ▸ | MEN1 | O00255 | 3/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | ITGB3 | P05106 | 3/20 | 0.42 |
| ▸ | ITGA2B | P08514 | 3/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | STS | P08842 | 1/20 | 0.39 |
| ▸ | CCKBR | P32239 | 1/20 | 0.38 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.37 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.37 |
| ▸ | JAK2 | O60674 | 1/20 | 0.37 |
| ▸ | JAK1 | P23458 | 1/20 | 0.37 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31163618 | 1.00 | MAPK1 (0.45) | MAPK1KMT2AMEN1ALDH1A1ITGB3 | |
| SCHEMBL182031 | 1.00 | MAPK1 (0.45) | MAPK1KMT2AMEN1ALDH1A1ITGB3 | |
| SCHEMBL15640769 | 0.91 | ALDH1A1 (0.43) | MAPK1KMT2AMEN1ALDH1A1L3MBTL1 | |
| SCHEMBL181801 | 0.88 | CCKBR (0.41) | MAPK1KMT2AMEN1ALDH1A1L3MBTL1 | |
| SCHEMBL181802 | 0.88 | CCKBR (0.41) | MAPK1KMT2AMEN1ALDH1A1L3MBTL1 | |
| SCHEMBL180948 | 0.87 | KMT2A (0.47) | MAPK1KMT2AMEN1ALDH1A1ITGB3 | |
| SCHEMBL180947 | 0.87 | KMT2A (0.47) | MAPK1KMT2AMEN1ALDH1A1ITGB3 | |
| SCHEMBL181676 | 0.84 | CCKBR (0.44) | MAPK1KMT2AMEN1ALDH1A1CCKBR | |
| SCHEMBL181677 | 0.84 | CCKBR (0.44) | MAPK1KMT2AMEN1ALDH1A1CCKBR | |
| SCHEMBL181545 | 0.84 | CCKBR (0.43) | MAPK1KMT2AMEN1ALDH1A1CCKBR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260146036-A1 | CRYSTALLINE FORMS | RAQUALIA PHARMA INC. (JP) | 2026-05-28 | — | — | US | disclosed |
| EP-4377309-A1 | CRYSTALLINE FORMS | RaQualia Pharma Inc. (JP) | 2024-06-05 | — | — | EP | disclosed |
| CN-117616022-A | Crystalline forms | 拉夸里亚创药株式会社 | 2024-02-27 | — | — | CN | disclosed |
| WO-2023008585-A1 | CRYSTALLINE FORMS | RAQUALIA PHARMA INC. (JP) | 2023-02-02 | — | — | WO | disclosed |
| EP-2401268-B1 | OXYINDOLE DERIVATIVES WITH MOTILIN RECEPTOR AGONISTIC ACTIVITY | RAQUALIA PHARMA INC (JP) | 2015-07-29 | — | — | EP | disclosed |
| US-8697877-B2 | Oxyindole derivatives with motilin receptor agonistic activity | RAQUALIA PHARMA INC. (JP) | 2014-04-15 | — | — | US | disclosed |
| EP-2401268-A1 | OXYINDOLE DERIVATIVES WITH MOTILIN RECEPTOR AGONISTIC ACTIVITY | RaQualia Pharma Inc (JP) | 2012-01-04 | — | — | EP | disclosed |
| US-20110312933-A1 | OXYINDOLE DERIVATIVES WITH MOTILIN RECEPTOR AGONISTIC ACTIVITY | RAQUALIA PHARMA INC. (JP) | 2011-12-22 | — | — | US | disclosed |
| WO-2010098145-A1 | OXYINDOLE DERIVATIVES WITH MOTILIN RECEPTOR AGONISTIC ACTIVITY | RAQUALIA PHARMA INC. (JP) | 2010-09-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110312933-A1 | OXYINDOLE DERIVATIVES WITH MOTILIN RECEPTOR AGONISTIC ACTIVITY | GPR68, GPR88, GPR52 | MAPK1 337/4885KMT2A 3436/4885MEN1 1651/4885 |
| US-20260146036-A1 | CRYSTALLINE FORMS | PRKCD, CCT8, CRYZ | MAPK1 735/4885KMT2A 342/4885MEN1 1387/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.